Impact Of Medicare RDS Tax Estimates Clarified; Employers Withhold Judgment On Reform Law
This article was originally published in The Pink Sheet Daily
The upcoming tax on the Medicare retiree drug subsidy will be less harmful to large employers than recent accounting figures from a number of firms would suggest, House Energy and Commerce Committee staff report April 14.
You may also be interested in...
Prescription drug coverage for millions of retirees currently provided by for-profit employer plans may change in the coming years as a result of the new tax on the Medicare retiree drug subsidy, signed into law as part of health reform March 23
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.